A similar reduction of VEGFR1 phosphorylation induced by bevacizumab, but associated with the inhibition of VEGFR2 activation through the blockade of VEGF-A, determined a much stronger decrease of tumor growth, neovascularization, and monocyte macrophage recruitment. Here, FLT1 is linked to neoplasm.